Taysha Gene Therapies, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.8M | $8.3M | $15.5M | $2.5M | — |
| Research and development | $86.4M | $66.0M | $56.8M | $91.2M | $131.9M |
| Operating expenses | $120.3M | $99.8M | $87.9M | $164.9M | $173.3M |
| Operating income | -$110.5M | -$91.5M | -$72.4M | -$162.4M | -$173.3M |
| Interest expense | $63,000 | $102,000 | $5.0M | $3.8M | $1.4M |
| Income tax expense | $0 | $0 | $0 | $0 | — |
| Net income | -$109.0M | -$89.3M | -$111.6M | -$166.0M | -$174.5M |
| Balance Sheet | |||||
| Cash and equivalents | $319.8M | $139.0M | $143.9M | $87.9M | $149.1M |
| Current assets | $324.6M | $142.1M | $149.9M | $96.4M | $159.6M |
| Total assets | $343.3M | $160.4M | $172.7M | $126.3M | $214.0M |
| Current liabilities | $26.6M | $26.2M | $36.8M | $62.8M | $51.7M |
| Total liabilities | $96.4M | $88.8M | $97.8M | $125.3M | $118.6M |
| Total debt | $50.0M | $40.0M | $40.0M | $40.0M | $40.0M |
| Stockholders' equity | $246.9M | $71.5M | $74.9M | $949,000 | $95.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$93.1M | -$81.2M | -$73.0M | -$88.4M | -$117.0M |
| Depreciation and amortization | $1.1M | $1.2M | $1.4M | $1.2M | $492,000 |
| Stock-based compensation | $13.3M | $13.1M | $7.9M | $18.0M | $18.2M |
| Capital expenditure | $738,000 | $374,000 | $3.9M | $20.6M | $15.3M |
| Free cash flow | -$93.8M | -$81.6M | -$76.9M | -$109.0M | -$132.3M |
| Impairments | $0 | $4.8M | $500,000 | $36.4M | $0 |
Shares outstanding 287.4M · Free float 81.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.